



Final v. October 05, 2016

Gynecologic Cancer InterGroup

Oct.27, 2016

TRANSLATIONAL RESEARCH BRAINSTORMING DAY

CHAIR: C. SCOTT

CO-CHAIR: C. GOURLEY

Expected outcomes of the TR Brainstorming Day:

- 1) To ensure that we improve translational component design for gynaecologic cancer trials;
- 2) To document such deliberations for a manuscript describing best practice on how to do translational research in future gynaecologic cancer;
- 3) To identify:
 - a. approaches that don't work
 - b. approaches that do work
 - c. aspirational goals

PROGRAM

Double Tree Hotel Fontana Park, Lisbon, Portugal (Liberdade I, Augusta I, Augusta II rooms)

8:00 – 8:30 **Registration**

8:30 – 8:35 **Welcome**

C. Scott (ANZGOG)

8:35 – 8:45 **Objectives**

C. Gourley (SGCTG)

Session 1: Topic 1 **Precision medicine in gynaecologic cancer**

Chair: M. Birrer (GOG)

8.45 – 9:25 Important definitions, expected outcomes from translation

A. Oza (PMHC)

9:25 – 9:45 Predictive biomarkers, pre-analytic variables, validation

J.Paul (Stats)

9:45 – 10:00 Liquid biopsy, predicting relapse and choice of next therapy

J. Brenton (SGCTG)

10:00 – 10:20 Experience from TransPortec
(Current/plans for endometrial)

C.Creutzberg (DGOG)

10:20 – 10:50 **BEVERAGE BREAK**

<u>Session 2: Topic 2</u>	Immunoprofiling: state of the art across gynae	Chair: H. Mackay (PMHC)
10:50 – 11:15	Overview of immune aspects – endometrial/cervical	H. Nijman (DGOG)
11:15 – 11:35	Ovarian Cancer	K. Hasagawa (GOTIC)
11:35 – 11:55	Microenvironment and immune responses	O. Dorigo (COGi)
11:55 – 12:00	Directions for afternoon Breakout Working Groups	C. Scott (ANZGOG)
12:00 – 13:00	LUNCH	
13:00 – 15:00	<u>Breakout Working Groups:</u>	

#1 - Topic: Harmonization of aspects related to tissue

Chair: D. Millan (SGCTG)

Co-Chair: P. Speiser (AGO-Au)

Ops rep: N. Le Fur

Stats rep: M. Brady

Preparing for the unknown -future translational opportunities

**D. Huntsman
(CCTG)**

QA/QC of sample acquisition

T. Bosse (Guest)

DISCUSSION

#2 - Topic: Appropriate validation of predictive biomarkers

Chair: E. Kohn (NCI US)

Co-Chair: P. Pollock (ANZGOG)

Ops rep: C. Blattler

Stats rep: J. Paul

Design of trials to validate biomarkers

L. McShane (NCI US)

Experience from RAIDs

S. Scholl (EORTC-GCG)

DISCUSSION

#3 - Topic: Roadblocks to completing translational goals in gynae research

Chair: I. McNeish (NCRI)

Co-Chair :I. Ray-Coquard (GINECO)

Ops rep: A. Negrouk

Stats rep: A.Reuss

Ensuring access for future research to clinically annotated tissue

**R. Glasspool
(SGCTG)**

Is governance improving? (global MTA, baskets/umbrellas)

**R. Edmondson
(NCRI)**

Streamlining of ethics – global harmonization

**A. Negrouk
(Harm Ops)**

DISCUSSION

15:00 – 15:30 BEVERAGE BREAK

15:30 – 16:00 Breakout Working Groups: regroup --- summarize for reports

16:00 – 18:00 Breakout Working Groups Reports and Panel Discussion

16:00 – 16:10 Harmonization of aspects related to tissue **D. Millan (SGCTG)**

DISCUSSION

16:40 – 16:50 Appropriate validation of predictive biomarkers **E. Kohn (NCI US)**

DISCUSSION

17:20 – 17:30 Roadblocks to completing translational goals **I. McNeish (NCRI)**

DISCUSSION

Panel: I. McNeish(NCRI), D. Huntsman(CCTG), D. Mezzanica(MITO), M. Bookman(GOG)

*Technical requirements to ensure consistent translational outcomes

*Appropriate validation of predictive biomarkers for efficacy within subgroups, toxicity and relationship with pharmacogenomics

18:00 View to the Future C. Gourley (SGCTG)

ADJOURN to GCIG DINNER